Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBSERVE: Immunogenicity and PK of Daclizumab HYP in RRMS
NCT01462318Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2011
- Primary completion
- Jan 2016
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 3 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started Nov 2011; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01462318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462318.